Viatris Inc (VTRS): Shareholders' Equity
$14.71B
As of 2025-12-31
$14.26B
As of 2026-06-30
-11.3%
3-year compound annual growth
-8.5%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $14.71B | -21.1% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $18.64B | -9.0% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $20.47B | -2.9% | 2026-02-26, Balance as of period end |
| 2022-12-31 | $21.07B | +2.8% | 2025-02-27, Balance as of period end |
| 2021-12-31 | $20.49B | -10.7% | 2024-02-28, Balance as of period end |
| 2020-12-31 | $22.95B | +93.2% | 2023-02-27, Balance as of period end |
| 2019-12-31 | $11.88B | -2.3% | 2022-02-28, Balance as of period end |
| 2018-12-31 | $12.17B | n/a | 2021-03-01, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Viatris Inc (VTRS) | 2025-12-31 | $14.71B | -21.1% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $31.26B | +6.5% |
| Vertex Pharmaceuticals Inc (VRTX) | 2025-12-31 | $18.67B | +13.7% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $7.91B | +47.1% |
| Bausch Health Companies Inc. (BHC) | 2025-12-31 | $377.00M | n/m |
| Zoetis Inc. (ZTS) | 2025-12-31 | $3.33B | -30.2% |
| Organon & Co. (OGN) | 2025-12-31 | $752.00M | +59.3% |
| BeOne Medicines Ltd. (ONC) | 2025-12-31 | $4.36B | +30.9% |
| Elanco Animal Health Inc (ELAN) | 2025-12-31 | $6.55B | +7.4% |
Compare VTRS, REGN, VRTX, TEVA side by side · Screen every company in Pharmaceutical Preparations ↗